The TPP Alberta Steering Committee has approved the move of two buprenorphine products from Type 1 to Type 2 drugs, and the addition of antibiotics to the Type 2 drug list.
Sublocade (injectable) and Probuphine (implant) are long acting formulations of buprenorphine typically used as Opioid Agonist Treatment for Opioid Use Disorders. These products are administered directly by a healthcare provider within specialized settings. The risk for diversion or misuse with these products is considered to be low. Both the products continue to be monitored through Netcare, PIN. With this change, TPP Alberta registration and the use of a TPP form will not be required to prescribe these products.
In addition, TPP Alberta recognizes antimicrobial resistance as an important issue of public health concern. To do its part to support optimized use, TPP Alberta has added antibiotics to its Type 2 drug list. These medications will be monitored through Netcare, PIN. Use of a TPP form or registration with TPP Alberta will not be required for prescribing antibiotics.